Roivant Sciences is trading at $37.58, up 4.27%, as Benzinga attributes Wednesday’s jump to Phase 3 CLARITY results showing brepocitinib treated noninfectious uveitis and reduced steroid reliance.
- The trials were announced October 21.
- The biotech sector is also strong, with XBI up 2.13%, supporting the move; no separate new company announcement surfaced for November 4.
- Roivant’s next scheduled earnings and business update is November 9.